Rybelsus Pancreatitis Warnings
In October 2025, warnings about pancreatitis were added to the Rybelsus “drug label”. Insofar as there were no Rybelsus pancreatitis warnings until October 2025, there is a possible “failure to warn” products liability claim for people who were diagnosed with Rybelsus pancreatitis side effects before October 2025.
From the Rybelsus (semaglutide) tablets Prescribing Information “Revised: 10/2025” version [PDF document], here is the actual text for these new Rybelsus pancreatitis warnings:
5.2 Acute Pancreatitis
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS [see Adverse Reactions (6)]. After initiation of RYBELSUS, observe patients carefully for signs and symptoms of pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue RYBELSUS and initiate appropriate management.
Rybelsus Pancreatitis Drug Injury Lawsuits
We are investigating Rybelsus pancreatitis drug injury lawsuits, with a focus on cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death. Those Rybeslus pancreatitis death cases would be filed against the responsible pharmaceutical company, Novo Nordisk.
The best possible Rybelsus pancreatitis drug injury lawsuits would be for people who were diagnosed with pancreatitis before October 2025 because, as indicated above, those cases could include a “failure to warn” legal allegation against the drug company Novo Nordisk.
And cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death would be the most significant Rybelsus drug injury lawsuits in terms of legal compensation and liability, and better than those cases where the pancreatitis went away after a person stopped using Rybelsus.
Finally, cases involving acute pancreatitis diagnosed after October 2025 while using Rybelsus are less likely to be filed as drug injury lawsuits against Novo Nordisk due to the Rybelsus drug label change above that added the pancreatitis drug side-effect warnings.
If you have a possible Rybelsus pancreatitis drug injury lawsuit that you would like to have investigated by drug injury attorney Tom Lamb, you can submit an online Case Evaluation Form. If you prefer, send him an email (TJL@LambLawOffice.com) or call him (910-256-2971).
[Read the article in full at Drug Injury Watch]Rybelsus
Free Case Evaluation
Strictly Confidential, No Obligation